Serveur d'exploration Tocilizumab - Analysis (2020)

Index « AbsEn.i » - entrée « introduction »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
introducing < introduction < intubation  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 19.
Ident.Authors (with country if any)Title
000034 (2020) Angelika Batta ; Bhupinder Singh Kalra ; Raj KhirasariaTrends in FDA drug approvals over last 2 decades: An observational study
000076 (2020) Philip George [Nouvelle-Zélande] ; Nathaniel Dasyam [Nouvelle-Zélande] ; Giulia Giunti [Nouvelle-Zélande] ; Brigitta Mester [Nouvelle-Zélande] ; Evelyn Bauer [Nouvelle-Zélande] ; Bethany Andrews [Nouvelle-Zélande] ; Travis Perera [Nouvelle-Zélande] ; Tess Ostapowicz [Nouvelle-Zélande] ; Chris Frampton [Nouvelle-Zélande] ; Peng Li [République populaire de Chine] ; David Ritchie [Australie] ; Catherine M. Bollard [États-Unis] ; Ian F. Hermans [Nouvelle-Zélande] ; Robert Weinkove [Nouvelle-Zélande]Third-generation anti-CD19 chimeric antigen receptor T-cells incorporating a TLR2 domain for relapsed or refractory B-cell lymphoma: a phase I clinical trial protocol (ENABLE)
000094 (2020) Ashish Sharma [Inde] ; Ashok Kumar [Inde] ; Alka Jha [Inde] ; Anunay Agarwal [Inde] ; Anoop Misra [Inde]The impact of obesity on inflammatory markers used in the assessment of disease activity in rheumatoid arthritis – a cross-sectional study
000121 (2020) Mattia Rosso [États-Unis] ; Shrishti Saxena [États-Unis] ; Tanuja Chitnis [États-Unis]Targeting IL-6 receptor in the treatment of neuromyelitis optica spectrum: a review of emerging treatment options.
000233 (2020) Giulia Cassone [Italie] ; Marco Sebastiani [Italie] ; Caterina Vacchi [Italie] ; Stefania Cerri [Italie] ; Carlo Salvarani [Italie] ; Andreina Manfredi [Italie]Pirfenidone for the treatment of interstitial lung disease associated to rheumatoid arthritis: a new scenario is coming?
000235 (2020) Nikita Mehta [États-Unis] ; Maryann Mazer-Amirshahi [États-Unis] ; Nour Alkindi [États-Unis]Pharmacotherapy in COVID-19; A narrative review for emergency providers
000307 (2020) Ethan S. Sen [Royaume-Uni] ; A V Ramanan [Royaume-Uni]Juvenile idiopathic arthritis-associated uveitis.
000314 (2020) Amit Rout [États-Unis] ; Ajaypaul Sukhi [États-Unis] ; Rahul Chaudhary [États-Unis] ; Kevin P. Bliden [États-Unis] ; Udaya S. Tantry [États-Unis] ; Paul A. Gurbel [États-Unis]Investigational drugs in phase II clinical trials for acute coronary syndromes.
000332 (2020) Ying-Ming Chiu [Taïwan] ; Der-Yuan Chen [Taïwan]Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics.
000382 (2020) Jacqueline M. Tarrant [États-Unis] ; René Galien [France] ; Wanying Li [États-Unis] ; Lovely Goyal [États-Unis] ; Yang Pan [États-Unis] ; Rachael Hawtin [États-Unis] ; Wangshu Zhang [États-Unis] ; Annegret Van Der Aa [Belgique] ; Peter C. Taylor [Royaume-Uni]Filgotinib, a JAK1 Inhibitor, Modulates Disease-Related Biomarkers in Rheumatoid Arthritis: Results from Two Randomized, Controlled Phase 2b Trials
000391 (2020) Slobodan M. Jankovic [Serbie] ; Izet Masic [Bosnie-Herzégovine]Evaluation of Preclinical and Clinical Studies Published in Medical Journals of Bosnia and Herzegovina: Methodology Issues
000428 (2020) Marion T. Turnbull [États-Unis] ; Jason L. Siegel [États-Unis] ; Tara L. Becker [États-Unis] ; Alana J. Stephens [États-Unis] ; A. Sebastian Lopez-Chiriboga [États-Unis] ; William D. Freeman [États-Unis]Early Bortezomib Therapy for Refractory Anti-NMDA Receptor Encephalitis
000440 (2020) Robert David Sandler [Royaume-Uni] ; Rachel Scarlett Tattersall [Royaume-Uni] ; Helene Schoemans [Belgique] ; Raffaella Greco [Italie] ; Manuela Badoglio [France] ; Myriam Labopin [France] ; Tobias Alexander [Allemagne] ; Kirill Kirgizov [Russie] ; Montserrat Rovira [Espagne] ; Muhammad Saif [Royaume-Uni] ; Riccardo Saccardi [Italie] ; Julio Delgado [Espagne] ; Zinaida Peric [Croatie] ; Christian Koenecke [Allemagne] ; Olaf Penack [Allemagne] ; Grzegorz Basak [Pologne] ; John Andrew Snowden [Royaume-Uni]Diagnosis and Management of Secondary HLH/MAS Following HSCT and CAR-T Cell Therapy in Adults; A Review of the Literature and a Survey of Practice Within EBMT Centres on Behalf of the Autoimmune Diseases Working Party (ADWP) and Transplant Complications Working Party (TCWP)
000454 (2020) He Huang [République populaire de Chine] ; Heng-Wei Wu [République populaire de Chine] ; Yong-Xian Hu [République populaire de Chine]Current advances in chimeric antigen receptor T-cell therapy for refractory/relapsed multiple myeloma
000470 (2020) Summer Chavez [États-Unis] ; Brit Long [États-Unis] ; Alex Koyfman [États-Unis] ; Stephen Y. Liang [États-Unis]Coronavirus Disease (COVID-19): A primer for emergency physicians
000488 (2020) Jennie H. Best [États-Unis] ; Steven C. Vlad [États-Unis] ; Jinglan Pei [États-Unis]Comparative Cost per Response for 4 Clinical Endpoints with Tocilizumab Monotherapy vs Adalimumab Monotherapy in a Head-to-Head Randomized Double-Blind Superiority Trial (ADACTA) in Patients with Rheumatoid Arthritis
000497 (2020) Satoshi Tsukuda [Japon] ; Tsukasa Ikeura [Japon] ; Takashi Ito [Japon] ; Koh Nakamaru [Japon] ; Masataka Masuda [Japon] ; Yuichi Hori [Japon] ; Manami Ikemune [Japon] ; Masato Yanagawa [Japon] ; Toshihiro Tanaka [Japon] ; Takashi Tomiyama [Japon] ; Takashi Yamaguchi [Japon] ; Yugo Ando [Japon] ; Kazushige Uchida [Japon] ; Toshiro Fukui [Japon] ; Akiyoshi Nishio [Japon] ; Rika Terasawa [Japon] ; Noboru Tanigawa [Japon] ; Kazuichi Okazaki [Japon]Clinical implications of elevated serum interleukin-6 in IgG4-related disease
000573 (2020) Izabela Szczygielska ; El Bieta Hernik ; Agnieszka Gazda ; Beata Kołodziejczyk ; Piotr GietkaAssessment of anti-HBs antibody concentration in children with juvenile idiopathic arthritis treated with biological drugs, vaccinated against viral type B hepatitis in infancy
000588 (2020) Gerd R. Burmester [Allemagne] ; Jeffrey R. Curtis [États-Unis] ; Huifeng Yun [États-Unis] ; Oliver Fitzgerald [Irlande (pays)] ; Kevin L. Winthrop [États-Unis] ; Valderilio F. Azevedo ; William F. C. Rigby [États-Unis] ; Keith S. Kanik [États-Unis] ; Cunshan Wang [États-Unis] ; Pinaki Biswas [États-Unis] ; Thomas Jones [États-Unis] ; Niki Palmetto [États-Unis] ; Thijs Hendrikx [États-Unis] ; Sujatha Menon [États-Unis] ; Ricardo Rojo [États-Unis]An Integrated Analysis of the Safety of Tofacitinib in Psoriatic Arthritis across Phase III and Long-Term Extension Studies with Comparison to Real-World Observational Data

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/2020/Analysis
HfdIndexSelect -h $EXPLOR_AREA/Data/2020/Analysis/AbsEn.i -k "introduction" 
HfdIndexSelect -h $EXPLOR_AREA/Data/2020/Analysis/AbsEn.i  \
                -Sk "introduction" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/2020/Analysis/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    2020
   |étape=   Analysis
   |type=    indexItem
   |index=    AbsEn.i
   |clé=    introduction
}}

Wicri

This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021